These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34243190)

  • 1. Prostate incidentaloma on 18F-fluorodeoxyglucose positron emission tomography: Diagnostic value of volumetric positron emission tomography parameters.
    Şahin Ö; Kaya B; Aydın Z; Şen AE; İyisoy MS; Aydın A
    Nuklearmedizin; 2021 Dec; 60(6):394-402. PubMed ID: 34243190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Value of Volume-Based Fluorine-18-Fluorodeoxyglucose PET/CT Parameters for Characterizing Thyroid Incidentaloma.
    Shi H; Yuan Z; Yuan Z; Yang C; Zhang J; Shou Y; Zhang W; Ping Z; Gao X; Liu S
    Korean J Radiol; 2018; 19(2):342-351. PubMed ID: 29520193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
    Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.
    Kim BH; Kim SJ; Kim H; Jeon YK; Kim SS; Kim IJ; Kim YK
    Nucl Med Commun; 2013 Sep; 34(9):868-76. PubMed ID: 23797273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 6. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of multi-modality functional imaging in differentiation between benign and malignant thyroid
    Shi H; Yuan Z; Yang C; Zhang J; Liu C; Sun J; Ye X
    Clin Transl Oncol; 2019 Nov; 21(11):1561-1567. PubMed ID: 30924093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis.
    Arslan E; Can Trabulus D; Mermut Ö; Şavlı TC; Çermik TF
    J Med Imaging Radiat Oncol; 2021 Feb; 65(1):38-45. PubMed ID: 33084216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic values of 2-[
    Han S; Kim YI; Oh JS; Seo SY; Park MJ; Lee GD; Choi S; Kim HR; Kim YH; Kim DK; Park SI; Ryu JS
    Eur Radiol; 2022 Feb; 32(2):1173-1183. PubMed ID: 34448035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer.
    Mohamadien NRA; Sayed MHM
    Nucl Med Commun; 2021 Jun; 42(6):656-664. PubMed ID: 33560720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total Lesion Glycolysis Obtained by FDG PET/CT in Diagnosing Solitary Pulmonary Nodules.
    Gungor S; Gunaydin UM; Yakar HI; Simsek ET; Akbiyik AG; Keskin H
    J Coll Physicians Surg Pak; 2023 Jan; 33(1):27-31. PubMed ID: 36597231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
    Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
    Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Mediastinal Tumors Using SUV
    Morita T; Tatsumi M; Ishibashi M; Isohashi K; Kato H; Honda O; Shimosegawa E; Tomiyama N; Hatazawa J
    Asia Ocean J Nucl Med Biol; 2017; 5(1):22-29. PubMed ID: 28840135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of metabolic tumour volume and total lesion glycolysis for dogs staged for appendicular osteosarcoma with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography.
    Griffin LR; Brody A; Lee BI
    Vet Comp Oncol; 2022 Mar; 20(1):59-68. PubMed ID: 33988286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of 18F-Fluorodeoxyglucose positron-emission tomography parameters in patients with biliary tract cancers: a meta-analysis.
    Zheng X; Shi Y; Kulabieke D; Wang Z; Cheng Y; Qian J
    BMC Med Imaging; 2024 Jan; 24(1):9. PubMed ID: 38166643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 20. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
    Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
    PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.